Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma

Vance G Nielsen, James K. Kirklin, James F. George

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Carbon monoxide derived from degradation of heme by heme oxygenase or carbon monoxide releasing molecules (CORMs) has been demonstrated to decrease thrombosis in vivo and to weakly inhibit platelet aggregation. We tested the hypothesis that carbon monoxide released from tricarbonyldichlororuthenium (II) dimer (CORM-2) would diminish the velocity of formation and strength of plasma thrombi as determined by thrombelastography. Normal plasma was exposed to 0 or 100 μmol/l CORM-2 or inactivated CORM-2 (iCORM-2), with coagulation initiated with tissue factor or celite (n ≤ 8 per condition). Additional experiments utilized factor XIII (FXIII) deficient plasma activated with celite. Coagulation kinetics was monitored with thrombelastography for 15 min. CORM-2, and to a lesser extent, iCORM-2, significantly (P < 0.05) increased the velocity of formation (122 and 56%, respectively) and strength (66 and 57%, respectively) of plasma clots initiated with either tissue factor or celite compared with thrombi not exposed to CORM-2 or iCORM. In FXIII deficient plasma CORM-2 significantly increased the velocity of clot formation (264%) and strength (240%). Carbon monoxide and iCORM-2 derived from CORM-2 markedly enhance the velocity of clot growth and strength. These findings serve as the rationale for further investigations to determine if CORMs could be utilized as hemostatic agents.

Original languageEnglish (US)
Pages (from-to)377-380
Number of pages4
JournalBlood Coagulation and Fibrinolysis
Volume20
Issue number5
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Carbon Monoxide
Thrombosis
Growth
Diatomaceous Earth
Thrombelastography
Factor XIII
Thromboplastin
Heme Oxygenase (Decyclizing)
Hemostatics
Heme
Platelet Aggregation

Keywords

  • Carbon monoxide
  • Carbon monoxide releasing molecule
  • Coagulation
  • Thrombelastography

ASJC Scopus subject areas

  • Hematology

Cite this

Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma. / Nielsen, Vance G; Kirklin, James K.; George, James F.

In: Blood Coagulation and Fibrinolysis, Vol. 20, No. 5, 07.2009, p. 377-380.

Research output: Contribution to journalArticle

@article{e91745bc0f894eae905bf28ad5f341e5,
title = "Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma",
abstract = "Carbon monoxide derived from degradation of heme by heme oxygenase or carbon monoxide releasing molecules (CORMs) has been demonstrated to decrease thrombosis in vivo and to weakly inhibit platelet aggregation. We tested the hypothesis that carbon monoxide released from tricarbonyldichlororuthenium (II) dimer (CORM-2) would diminish the velocity of formation and strength of plasma thrombi as determined by thrombelastography. Normal plasma was exposed to 0 or 100 μmol/l CORM-2 or inactivated CORM-2 (iCORM-2), with coagulation initiated with tissue factor or celite (n ≤ 8 per condition). Additional experiments utilized factor XIII (FXIII) deficient plasma activated with celite. Coagulation kinetics was monitored with thrombelastography for 15 min. CORM-2, and to a lesser extent, iCORM-2, significantly (P < 0.05) increased the velocity of formation (122 and 56{\%}, respectively) and strength (66 and 57{\%}, respectively) of plasma clots initiated with either tissue factor or celite compared with thrombi not exposed to CORM-2 or iCORM. In FXIII deficient plasma CORM-2 significantly increased the velocity of clot formation (264{\%}) and strength (240{\%}). Carbon monoxide and iCORM-2 derived from CORM-2 markedly enhance the velocity of clot growth and strength. These findings serve as the rationale for further investigations to determine if CORMs could be utilized as hemostatic agents.",
keywords = "Carbon monoxide, Carbon monoxide releasing molecule, Coagulation, Thrombelastography",
author = "Nielsen, {Vance G} and Kirklin, {James K.} and George, {James F.}",
year = "2009",
month = "7",
doi = "10.1097/MBC.0b013e32832ca3a3",
language = "English (US)",
volume = "20",
pages = "377--380",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma

AU - Nielsen, Vance G

AU - Kirklin, James K.

AU - George, James F.

PY - 2009/7

Y1 - 2009/7

N2 - Carbon monoxide derived from degradation of heme by heme oxygenase or carbon monoxide releasing molecules (CORMs) has been demonstrated to decrease thrombosis in vivo and to weakly inhibit platelet aggregation. We tested the hypothesis that carbon monoxide released from tricarbonyldichlororuthenium (II) dimer (CORM-2) would diminish the velocity of formation and strength of plasma thrombi as determined by thrombelastography. Normal plasma was exposed to 0 or 100 μmol/l CORM-2 or inactivated CORM-2 (iCORM-2), with coagulation initiated with tissue factor or celite (n ≤ 8 per condition). Additional experiments utilized factor XIII (FXIII) deficient plasma activated with celite. Coagulation kinetics was monitored with thrombelastography for 15 min. CORM-2, and to a lesser extent, iCORM-2, significantly (P < 0.05) increased the velocity of formation (122 and 56%, respectively) and strength (66 and 57%, respectively) of plasma clots initiated with either tissue factor or celite compared with thrombi not exposed to CORM-2 or iCORM. In FXIII deficient plasma CORM-2 significantly increased the velocity of clot formation (264%) and strength (240%). Carbon monoxide and iCORM-2 derived from CORM-2 markedly enhance the velocity of clot growth and strength. These findings serve as the rationale for further investigations to determine if CORMs could be utilized as hemostatic agents.

AB - Carbon monoxide derived from degradation of heme by heme oxygenase or carbon monoxide releasing molecules (CORMs) has been demonstrated to decrease thrombosis in vivo and to weakly inhibit platelet aggregation. We tested the hypothesis that carbon monoxide released from tricarbonyldichlororuthenium (II) dimer (CORM-2) would diminish the velocity of formation and strength of plasma thrombi as determined by thrombelastography. Normal plasma was exposed to 0 or 100 μmol/l CORM-2 or inactivated CORM-2 (iCORM-2), with coagulation initiated with tissue factor or celite (n ≤ 8 per condition). Additional experiments utilized factor XIII (FXIII) deficient plasma activated with celite. Coagulation kinetics was monitored with thrombelastography for 15 min. CORM-2, and to a lesser extent, iCORM-2, significantly (P < 0.05) increased the velocity of formation (122 and 56%, respectively) and strength (66 and 57%, respectively) of plasma clots initiated with either tissue factor or celite compared with thrombi not exposed to CORM-2 or iCORM. In FXIII deficient plasma CORM-2 significantly increased the velocity of clot formation (264%) and strength (240%). Carbon monoxide and iCORM-2 derived from CORM-2 markedly enhance the velocity of clot growth and strength. These findings serve as the rationale for further investigations to determine if CORMs could be utilized as hemostatic agents.

KW - Carbon monoxide

KW - Carbon monoxide releasing molecule

KW - Coagulation

KW - Thrombelastography

UR - http://www.scopus.com/inward/record.url?scp=68149089854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149089854&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32832ca3a3

DO - 10.1097/MBC.0b013e32832ca3a3

M3 - Article

VL - 20

SP - 377

EP - 380

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 5

ER -